FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

M Wirth

Research Profile

Chemicals & Drugs

Disorders

Procedures

Physiology

Disease Progression

Concepts & Ideas

Devices

Placebos

Co-author Network

Publications

TOP 3
M Wirth; Chris J Tyrrell; Karl P J Delaere; M Sánchez-Chapado; J Ramon; D M A Wallace; J Hetherington; F Pina; C F Heyns; S Navani; Jon Armstrong
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
M Wirth; Chris J Tyrrell; Karl P J Delaere; M Sánchez-Chapado; J Ramon; D M A Wallace; J Hetherington; F Pina; C Heyns; T Borchers; Tom Morris; Jon Armstrong
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
William A See; Peter Iversen; M Wirth; D McLeod; L Garside; Tom Morris
Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of M Wirth (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: M Wirth; Chris J Tyrrell; Karl P J Delaere; M Sánchez-Chapado; J Ramon; D M A Wallace; J Hetherington; F Pina; C F Heyns; S Navani; Jon Armstrong
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
Prostate cancer and prostatic diseases 2007;10(1):87-93.
2005: M Wirth; Chris J Tyrrell; Karl P J Delaere; M Sánchez-Chapado; J Ramon; D M A Wallace; J Hetherington; F Pina; C Heyns; T Borchers; Tom Morris; Jon Armstrong
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
Prostate cancer and prostatic diseases 2005;8(2):194-200.
2003: William A See; Peter Iversen; M Wirth; D McLeod; L Garside; Tom Morris
Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.
European urology 2003;44(5):512-7; discussion 517-8.
2001: M Wirth; Chris J Tyrrell; M Wallace; Karl P J Delaere; M Sánchez-Chapado; J Ramon; J Hetherington; F Pina; C F Heynes; T M Borchers; Tom Morris; A Stone
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
Urology 2001;58(2):146-51.
2001: M Wirth
Delaying/reducing the risk of clinical tumour progression after primary curative procedures.
European urology 2001;40 Suppl 2():17-23.
1999: M Wirth; Michael Froehner
A review of studies of hormonal adjuvant therapy in prostate cancer.
European urology 1999;36 Suppl 2():14-9.